Aravive Inc (ARAV)

Overview

Aravive, Inc. is a clinical-stage biopharmaceutical company headquartered in Houston, Texas. The company is dedicated to the discovery and development of innovative treatments aimed at addressing life-threatening conditions, such as cancer and fibrosis. Aravive's principal therapeutic candidate, batiraxcept, is an ultrahigh-affinity decoy protein engineered to disrupt the GAS6-AXL signaling pathway, which is critical in various malignant conditions.

Currently, batiraxcept is undergoing a Phase III clinical trial for patients suffering from platinum-resistant recurrent ovarian cancer. Additionally, it is being investigated in Phase Ib/II studies for clear cell renal cell carcinoma and pancreatic adenocarcinoma. In addition to batiraxcept, Aravive has developed a pipeline product, AVB-S6, which is a soluble Fc-fusion protein designed to inhibit the activation of the same GAS6-AXL pathway, thereby potentially providing therapeutic benefits. The company actively pursues strategic collaborations and partnerships to bolster its research and development efforts. Aravive has established a tie-up with WuXi Biologics (Hong Kong) Limited to create novel, high-affinity bispecific antibodies that target cancer and fibrosis. Furthermore, a license agreement with 3D Medicines Inc. allows for the development and commercialization of products that feature batiraxcept as the sole active ingredient across mainland China, Taiwan, Hong Kong, and Macau. Originally, the company was incorporated as Versartis, Inc. in 2008 and later rebranded to Aravive, Inc. in October 2018.

Products and Services

• Batiraxcept: This is Aravive's primary therapeutic candidate, functioning as an ultrahigh-affinity decoy protein. It targets the GAS6-AXL signaling pathway and is currently in Phase III clinical trials for treating platinum-resistant recurrent ovarian cancer, alongside Phase Ib/II evaluations for other oncological conditions such as clear cell renal cell carcinoma and pancreatic adenocarcinoma.
• AVB-S6: A pipeline candidate designed as a soluble Fc-fusion protein with the goal of blocking GAS6-AXL pathway activation. This product is still in development stages and may offer new therapeutic options for patients afflicted with diseases related to this signaling pathway.
• Strategic Partnerships: Aravive has forged important collaborations to expand its research capabilities. They have partnered with WuXi Biologics to innovate high-affinity bispecific antibodies targeting both cancer and fibrosis, thereby broadening the scope of potential treatments emerging from their research efforts.
• License Agreement with 3D Medicines Inc.: This agreement grants rights to develop and commercialize products containing batiraxcept for the treatment of oncological diseases in key regions, including mainland China, Taiwan, Hong Kong, and Macau. This partnership is crucial for market expansion and increasing accessibility to Aravive’s innovative therapies.